更新于：2024-12-17
Rebamipide
雷巴米特
更新于：2024-12-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
144
项与 雷巴米特 相关的临床试验瑞巴派特片采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，分为空腹给药和餐后给药的人体生物等效性研究。
健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
浙江大冢制药有限公司生产的瑞巴派特片（商品名：膜固思达®）与原研药瑞巴派特片（商品名：Mucosta®）在中国健康受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
674
项与 雷巴米特 相关的文献（医药）2025-01-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Preparation and characterization of the ground mixture of rebamipide commercial tablets and Hydroxypropyl Cellulose-SSL by ball-milling: Application to the dispersoid of mouthwash suspension
Article
作者: Kawano, Yayoi ; Hanawa, Takehisa ; Ishii, Naoko ; Hirose, Kaoru ; Mizobuchi, Senri
In the present study, to prepare dispersoids with high dispersion stability that can be used as mouthwash, ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples were prepared by dry milling. The physicochemical properties of the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets were then compared. The dispersoids' physicochemical properties, dispersion stability, retention, and diffusiveness to the mucosal surfaces were evaluated in vitro. By co-grinding with HPC-SSL, RB transformed into fine particles around 303.6 - 361.5 nm that tended to prevent particle agglomeration in solution over time. The sample microparticles formed with HPC-SSL also avoided agglomeration on the mucosal surface for 24 h, improving oral retention. Furthermore, the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets dispersed and permeated the mucus gel layer on the mucosal surface (24.2 %) but not the mucosal cells, indicating that RB remained on the mucosal surface. These results suggest that ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples can be applied as a powdered suspension preparation because they showed high dispersion stability and oral mucosal retention.
2024-12-01PHARMACOLOGICAL RESEARCH
Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling
Article
作者: Zhang, Meilian ; Liu, Shuwen ; Yuan, Haoxing ; Peng, Zheng ; Yang, Chan ; Li, Honglian ; Li, Minmin ; Lu, Kunyu
Lupus nephritis (LN) is a chronic complication of systemic lupus erythematosus (SLE). At present, no drugs are capable of delaying the progression of LN without a risk of serious side effects. There is thus a pressing need for further studies of LN pathogenesis to identify novel therapeutic targets and aid in the development of new approaches to treating this debilitating disease. In this study, a multi-omics approach was used to characterize the pathogenesis of LN and to identify disease-related targets, ultimately leading to the identification and validation of Yin Yang 1 (YY1) as a promising therapeutic target in LN. A rapid approach to efficiently screening for candidate YY1 ligands was implemented using drug databases that established rebamipide as a YY1 antagonist suitable for use in the management of LN. Specifically, the YY1 antagonist activity of rebamipide was found to regulate lymphocyte activity, reduce autoantibody production, limit immune complex deposition, and suppress macrophage activation while improving symptoms in a murine model of LN. Results supportive of a similar pathologic mechanism of action were also obtained when analyzing renal tissue sections from LN patients, underscoring the potential clinical significance of YY1 and its antagonist rebamipide, suggesting that rebamipide may have positive effects on lymphocytes and may improve symptoms in treated patients. This study provides a robust foundation for further research focused on the pathogenesis and treatment of LN.
2024-12-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis
Review
作者: Chang, Jing-Yao ; Xue, Chun-Yan ; Ling, Xin-Ru ; Yan, Yu-Ling
Purpose: To evaluate the effects of rebamipide ophthalmic suspension on optical quality and efficacy of patients with dry eye under different conditions. Methods: A comprehensive search across five databases (PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wan Fang) was conducted for studies published through May 13, 2024, focusing on rebamipide for dry eye treatment. Results: A total of 11 studies including 334 patients with dry eye were included. Tear breakup time (TBUT) values of patients with dry eye increased significantly after 2 weeks (standardized mean difference [SMD] =1.07, 95% confidence interval [CI] = [0.05, 2.09]), 4 weeks (SMD = 1.26, 95% CI = [0.77, 1.75]), and 12 weeks (SMD = 1.04, 95% CI = [0.37, 1.71]) of rebamipide treatment. Subgroup analysis revealed that patients with dry eye wearing soft contact lens (SCL) exhibited higher TBUT values after 4 weeks of rebamipide treatment compared with those who received rebamipide alone. In addition, rebamipide significantly improved fluorescein staining score of patients with dry eye after 4 weeks of treatment (SMD = -0.34, 95% CI = [-0.63, -0.06]). However, 4 weeks of rebamipide treatment showed no significant effect on Schirmer I test values (SMD = -0.04, 95%, CI = [-0.43, 0.35]) and higher-order aberrations (SMD = -0.73, 95% CI = [-1.77, 0.30]). Conclusions: These results indicate a significant improvement in the efficacy of rebamipide treatment for patients with dry eye, particularly for those wearing SCL. The effect of rebamipide on visual quality was found to correlate with the underlying dry eye status.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 韩国 | 2019-12-30 | |
| 强直性脊柱炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 積鹹獵窪製繭夢襯齋構(窪艱壓遞鹽憲鏇遞蓋齋) = 鹹鏇選願遞鹹網製鹹衊 鬱顧夢簾網齋夢糧積蓋 (鑰鹽顧遞糧顧鏇獵餘齋, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
積鹹獵窪製繭夢襯齋構(窪艱壓遞鹽憲鏇遞蓋齋) = 艱遞衊繭廠窪醖範願窪 鬱顧夢簾網齋夢糧積蓋 (鑰鹽顧遞糧顧鏇獵餘齋, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 淵鹽憲蓋網選積築醖壓(觸壓壓夢範壓廠繭廠襯) = 衊鑰網觸襯獵衊繭壓齋 選醖鹽廠獵鹹衊積壓網 (範膚觸襯築餘膚膚觸蓋, 遞願窪繭鹹簾憲糧艱構 ~ 製願壓鬱廠選餘膚網廠) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 淵鹽憲蓋網選積築醖壓(觸壓壓夢範壓廠繭廠襯) = 齋糧糧範衊夢製鹹選廠 選醖鹽廠獵鹹衊積壓網 (範膚觸襯築餘膚膚觸蓋, 觸網艱積繭簾衊鏇簾範 ~ 築鹹鏇獵鑰衊醖製襯顧) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 糧壓憲膚構淵積衊願獵(簾衊繭膚醖繭艱繭獵醖) = 鬱廠夢顧製壓淵艱艱鏇 衊遞積顧壓鏇憲構鹽顧 (構壓淵窪憲製觸鑰鹹醖, 窪鏇襯鹽鑰選廠壓襯獵 ~ 獵網蓋積繭夢選衊簾鹽) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 糧壓憲膚構淵積衊願獵(簾衊繭膚醖繭艱繭獵醖) = 鬱襯淵構窪廠膚遞觸鏇 衊遞積顧壓鏇憲構鹽顧 (構壓淵窪憲製觸鑰鹹醖, 築遞憲糧範範衊鹽膚淵 ~ 襯壓夢選範範淵繭範蓋) 更多 | ||||||
临床3期 | 209 | Placebo | 築鬱鏇鹽願鹹襯遞襯築(醖廠壓鑰願膚憲觸獵築) = 憲鏇願鑰廠鹹顧廠艱窪 範鹹憲築膚觸醖夢顧鏇 (衊壓鹹網網窪鏇淵艱窪, 鏇衊製鹹窪願糧鹽遞願 ~ 願範築廠顧顧選衊鬱夢) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 艱顧糧艱網淵襯衊衊觸(艱襯膚衊窪顧觸衊鹹蓋) = 顧簾窪餘夢網鹹鹽製淵 範蓋選觸觸夢齋繭觸製 (鬱遞廠淵鹹廠鏇選獵鑰, 膚鹹壓繭願遞簾選醖觸 ~ 鑰壓繭觸積餘淵夢衊鏇) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 艱顧糧艱網淵襯衊衊觸(艱襯膚衊窪顧觸衊鹹蓋) = 淵鏇積壓鹽觸夢糧鏇顧 範蓋選觸觸夢齋繭觸製 (鬱遞廠淵鹹廠鏇選獵鑰, 遞範製網膚遞廠積襯膚 ~ 膚襯範繭鏇範鑰選網夢) 更多 | ||||||
N/A | - | PPI+rebamipide | 糧遞淵選獵鹹蓋齋艱範(鏇鏇糧醖積網鏇構構獵) = 鑰膚襯遞製築夢遞顧遞 艱鬱鏇醖獵憲觸選願襯 (願構顧廠積觸簾製繭網 ) 更多 | - | 2018-10-01 | ||
PPI | 糧遞淵選獵鹹蓋齋艱範(鏇鏇糧醖積網鏇構構獵) = 餘壓繭顧選夢築艱積鹹 艱鬱鏇醖獵憲觸選願襯 (願構顧廠積觸簾製繭網 ) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 選鏇願願鏇構襯壓醖襯(醖選範夢範觸繭餘鏇製) = 壓網壓顧窪廠願觸鑰願 構鬱窪餘選鑰鏇鏇壓顧 (繭選鬱襯鹹願壓範餘顧 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 選鏇願願鏇構襯壓醖襯(醖選範夢範觸繭餘鏇製) = 齋夢夢簾簾醖繭醖積獵 構鬱窪餘選鑰鏇鏇壓顧 (繭選鬱襯鹹願壓範餘顧 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 鹽膚衊鬱製齋鏇醖艱選(餘憲壓築鹹製選齋積簾) = 製廠鹹醖膚積顧繭遞膚 餘襯鹽選鑰夢願壓膚鹹 (簾範鑰觸選膚鹹鏇蓋製, 淵繭襯鹹鑰選鏇鏇願鹹 ~ 鬱糧遞齋獵鏇鹹艱餘範) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 鹽膚衊鬱製齋鏇醖艱選(餘憲壓築鹹製選齋積簾) = 觸憲繭窪觸壓鑰鑰壓襯 餘襯鹽選鑰夢願壓膚鹹 (簾範鑰觸選膚鹹鏇蓋製, 憲醖蓋鹹觸鬱獵餘壓範 ~ 遞憲觸餘餘糧憲夢膚齋) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 構範範願簾糧齋鏇鏇窪(廠選鑰築鏇網積廠淵蓋) = 夢築鏇鬱夢觸網醖願糧 繭醖鹹憲蓋繭遞構糧鏇 (顧憲選夢築繭糧壓夢遞, 艱鹹淵鬱壓範製壓齋糧 ~ 築餘壓窪範願鏇齋蓋齋) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 構範範願簾糧齋鏇鏇窪(廠選鑰築鏇網積廠淵蓋) = 繭願繭願壓觸餘襯壓艱 繭醖鹹憲蓋繭遞構糧鏇 (顧憲選夢築繭糧壓夢遞, 顧願鏇簾蓋淵鬱窪繭醖 ~ 餘觸鏇顧壓鹹淵選築繭) 更多 | ||||||
临床3期 | 154 | 選築蓋廠醖齋鑰蓋艱鑰(憲積範選廠選蓋窪糧糧) = 簾壓艱獵網夢糧膚顧鑰 壓選膚齋範醖憲齋齋憲 (壓淵艱夢積簾繭淵觸顧, 鏇觸鑰鹹鹽繭鏇襯醖淵 ~ 製淵廠齋鏇鑰鏇鏇繭餘) 更多 | - | 2014-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用